Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher (NYSE: TMO) priced a €2.1 billion offering of euro-denominated senior notes, expected to close on or about December 1, 2025. The issuance comprises €1.0B floating-rate notes due 2027 and €1.1B fixed-rate notes due 2035 with a 3.628% coupon. The notes are fully guaranteed by Thermo Fisher and will pay interest quarterly (floating) or annually (fixed). Net proceeds are for general corporate purposes, including acquisitions, debt repayment, working capital, capex, or share repurchases.
Thermo Fisher Scientific (NYSE: TMO) announced 510(k) clearance in the U.S. on November 12, 2025 for the EXENT Analyser and Immunoglobulin Isotypes (GAM) Assay, an automated diagnostic platform to aid in the diagnosis of multiple myeloma and related disorders.
The EXENT System claims enhanced sensitivity for detecting and isotyping M‑proteins, automated workflows with up to six hours of walkaway time per shift, no prior mass spectrometry experience required, and recent authorization for sale in Canada; availability is listed for multiple countries.
Thermo Fisher Scientific (NYSE:TMO) announced that its Board of Directors has authorized the repurchase of $5 billion of its common stock in the open market or in negotiated transactions.
The authorization has no expiration date, letting the company repurchase shares over time subject to market conditions and internal decisions.
Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.43 per common share. The dividend is payable on January 15, 2026 to shareholders of record as of December 15, 2025.
Thermo Fisher Scientific (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings for $8.875 billion in cash plus potential earnouts and follow‑up payments.
Clario, with ~4,000 employees and expected $1.25 billion revenue in 2025, provides endpoint data solutions that supported ~70% of FDA drug approvals over the past decade. Thermo Fisher expects the deal to be immediately accretive to adjusted EPS by $0.45 in year one, to deliver ~$175M adjusted operating income from synergies by year five, and to grow the business at high single digits under Thermo Fisher ownership. Close is expected by mid‑2026, subject to approvals; funding will include debt financing and cash on hand.
Thermo Fisher Scientific (NYSE: TMO) reported Q3 2025 results for the quarter ended September 27, 2025. Revenue rose 5% to $11.12 billion with organic revenue growth of 3%. GAAP diluted EPS was $4.27 (in-line year‑over‑year) and adjusted EPS grew 10% to $5.79. Adjusted operating margin improved to 23.3% and adjusted operating income was $2.59 billion. The company completed acquisitions of a Filtration and Separation business and Sanofi’s Ridgefield sterile fill‑finish site, repurchased $1.0 billion of stock, launched several products, received an FDA approval for an Oncomine Dx test, and announced a strategic collaboration with OpenAI.
Thermo Fisher Scientific (NYSE: TMO) announced a strategic collaboration with OpenAI on October 16, 2025 to embed OpenAI APIs across product development, service delivery, customer engagement and operations.
Key initiatives include applying OpenAI to Thermo Fisher’s PPD clinical research business to shorten clinical trial cycle time, integrating AI into the Accelerator Drug Development solution across Phase I–III and manufacturing, and rolling out ChatGPT Enterprise to employees to build AI fluency.
Thermo Fisher Scientific (NYSE:TMO), the world leader in serving science, has scheduled its Q3 2025 earnings release and conference call for Wednesday, October 22, 2025. The financial results will be released before market opening, followed by a conference call at 8:30 a.m. ET.
Investors can access the call by dialing (833) 470-1428 within the U.S. or (404) 975-4839 internationally, using access code 761271. A live webcast will be available on the company's investor relations website. The earnings materials and call replay will remain accessible through February 1, 2026.
Thermo Fisher Scientific (NYSE: TMO) has announced the pricing of a $2.5 billion senior notes offering across four tranches with different maturities and interest rates. The offering includes: $500 million of 4.200% notes due 2031, $750 million of 4.473% notes due 2032, $750 million of 4.794% notes due 2035, and $500 million of 4.894% notes due 2037.
The offering is expected to close around October 7, 2025. The company plans to use the proceeds for general corporate purposes, including potential acquisitions, debt refinancing, working capital, capital expenditures, or share repurchases. J.P. Morgan Securities, ING Financial Markets, Mizuho Securities USA, and Scotia Capital are serving as joint book-running managers for the offering.
Thermo Fisher Scientific (NYSE:TMO) has completed the acquisition of Sanofi's sterile fill-finish and packaging facility in Ridgefield, New Jersey. The strategic move expands TMO's U.S. manufacturing capabilities within its Laboratory Products and Biopharma Services segment.
The deal includes retaining over 200 experienced employees and continuing to manufacture Sanofi's therapies at the site while expanding capacity for other pharma and biotech customers. The Ridgefield facility joins TMO's existing U.S. sterile fill-finish network, which includes sites in Greenville, North Carolina and Plainville, Massachusetts.
The acquisition strengthens TMO's Accelerator™ Drug Development 360° CDMO and CRO solutions, enhancing its pharmaceutical value chain services for emerging biotech and biopharma companies.